SG10201805039UA - Protease resistant peptides - Google Patents
Protease resistant peptidesInfo
- Publication number
- SG10201805039UA SG10201805039UA SG10201805039UA SG10201805039UA SG10201805039UA SG 10201805039U A SG10201805039U A SG 10201805039UA SG 10201805039U A SG10201805039U A SG 10201805039UA SG 10201805039U A SG10201805039U A SG 10201805039UA SG 10201805039U A SG10201805039U A SG 10201805039UA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- protease
- resistant peptides
- protease resistant
- resistant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
Abstract
The present invention provides protease-resistant peptides, methods of making such peptides, as well as compositions comprising protease-resistant peptides and method of treatment utilizing such peptides. Incorporation of alpha-methyl-functionalized amino acids directly into the main chain during standard peptide synthesis via the methodologies described herein has been determined to produce protease-resistant peptides. [FIG. 1]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361915662P | 2013-12-13 | 2013-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201805039UA true SG10201805039UA (en) | 2018-07-30 |
Family
ID=52021207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805039UA SG10201805039UA (en) | 2013-12-13 | 2014-12-10 | Protease resistant peptides |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160318987A1 (en) |
EP (2) | EP3080153A2 (en) |
JP (1) | JP2017502003A (en) |
KR (1) | KR20160098406A (en) |
CN (1) | CN105849123A (en) |
AU (1) | AU2014363547A1 (en) |
BR (1) | BR112016013157A2 (en) |
CA (1) | CA2933405A1 (en) |
MX (1) | MX2016007407A (en) |
SG (1) | SG10201805039UA (en) |
WO (1) | WO2015086686A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI726889B (en) | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | Protease-resistant lipidated peptides |
US20190055279A1 (en) * | 2015-10-28 | 2019-02-21 | Tufts University | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
WO2017211922A2 (en) | 2016-06-09 | 2017-12-14 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
PE20211417A1 (en) | 2018-04-05 | 2021-08-02 | Sun Pharmaceutical Ind Ltd | NEW GLP-1 ANALOGS |
TW202346323A (en) * | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | Glp-1 and glucagon dual agonist peptides with improved biological stability |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143346A0 (en) * | 1998-12-07 | 2002-04-21 | Sod Conseils Rech Applic | Analogues of glp-1 |
US8445433B2 (en) * | 2006-02-08 | 2013-05-21 | Lonza Ag | Synthesis of glucagon-like peptide |
WO2007139589A1 (en) * | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
WO2008023050A1 (en) * | 2006-08-25 | 2008-02-28 | Novo Nordisk A/S | Acylated exendin-4 compounds |
ATE554098T1 (en) * | 2007-12-11 | 2012-05-15 | Cadila Healthcare Ltd | PEPTIDOMIMETICA WITH GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITIES |
ES2354488T3 (en) * | 2008-04-18 | 2011-03-15 | F. Hoffmann-La Roche Ag | ALFA-N-METHYLATION OF AMINO ACIDS. |
US20120264685A1 (en) * | 2009-10-22 | 2012-10-18 | Rajesh Bahekar | Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist |
US20130143800A1 (en) * | 2011-11-07 | 2013-06-06 | Research Development Foundation | Combination therapies to treat diabetes |
WO2014049610A2 (en) * | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
WO2014088631A1 (en) * | 2012-12-06 | 2014-06-12 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
-
2014
- 2014-12-10 WO PCT/EP2014/077240 patent/WO2015086686A2/en active Application Filing
- 2014-12-10 SG SG10201805039UA patent/SG10201805039UA/en unknown
- 2014-12-10 US US15/103,607 patent/US20160318987A1/en not_active Abandoned
- 2014-12-10 KR KR1020167018887A patent/KR20160098406A/en not_active Application Discontinuation
- 2014-12-10 MX MX2016007407A patent/MX2016007407A/en unknown
- 2014-12-10 JP JP2016538037A patent/JP2017502003A/en active Pending
- 2014-12-10 AU AU2014363547A patent/AU2014363547A1/en not_active Abandoned
- 2014-12-10 EP EP14809857.7A patent/EP3080153A2/en not_active Withdrawn
- 2014-12-10 EP EP18182275.0A patent/EP3415526A1/en not_active Withdrawn
- 2014-12-10 BR BR112016013157A patent/BR112016013157A2/en not_active Application Discontinuation
- 2014-12-10 CN CN201480067307.1A patent/CN105849123A/en active Pending
- 2014-12-10 CA CA2933405A patent/CA2933405A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2015086686A3 (en) | 2015-10-29 |
CA2933405A1 (en) | 2015-06-18 |
AU2014363547A1 (en) | 2016-06-30 |
US20160318987A1 (en) | 2016-11-03 |
BR112016013157A2 (en) | 2017-09-26 |
WO2015086686A2 (en) | 2015-06-18 |
EP3080153A2 (en) | 2016-10-19 |
KR20160098406A (en) | 2016-08-18 |
MX2016007407A (en) | 2016-12-12 |
JP2017502003A (en) | 2017-01-19 |
CN105849123A (en) | 2016-08-10 |
EP3415526A1 (en) | 2018-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201805039UA (en) | Protease resistant peptides | |
AU2018260800B2 (en) | Hepcidin analogues and uses therof | |
MX2014001372A (en) | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer. | |
MY187486A (en) | Cysteine protease | |
MX2021005254A (en) | Recombinant production of a collagen peptide preparation and use thereof. | |
MY188696A (en) | Cysteine protease | |
MX2017009595A (en) | Anti-senescence compounds and uses thereof. | |
UA118167C2 (en) | Peptides and their use | |
MX2019007152A (en) | Novel peptide. | |
EA201890815A1 (en) | AMINO ACID COMPOSITIONS WITH MODIFIED DELIVERY FOR ORAL ADMINISTRATION | |
MX2016008355A (en) | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof. | |
MY182177A (en) | Method for masking bitterness of composition containing collagen peptide | |
AR120721A2 (en) | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE | |
MX2018014966A (en) | Protease-resistant mono-lipidated peptides. | |
PH12017502259A1 (en) | Protease-resistant lipidated glp-1 analogs | |
MX2023005421A (en) | Anti-vegf protein compositions and methods for producing the same. | |
NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
MX362058B (en) | Synthetic pntx(19) peptide, pharmaceutical compositions and use. | |
NZ744289A (en) | Composition containing amino acids | |
WO2014152831A3 (en) | Targeting peptides and uses thereof | |
WO2014039074A3 (en) | Therapeutic compositions and related methods | |
GB201118201D0 (en) | Novel peptides | |
MX2010011055A (en) | Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopetidases. | |
WO2015200768A3 (en) | Pharmacologic treatments of menière's disease | |
MX2019001320A (en) | Composition and use of a peptide. |